Biotech firm Vyome Therapeutics to go public via reverse merger with Nasdaq-listed Reshape Lifesciences

Vyome Therapeutics, a biotech company backed by Manipal group chief Ranjan Pai, will go public in the US through a reverse merger with US-based Reshape Lifesciences. Pai, along with investors Remus Capital and Iron Pillar will invest at least $7.3 million in the merged entity through a private placement.